Jiangxi Biological (06915.HK) opened 38.5% higher on the gray market ahead of its June 30 Hong Kong Main Board listing. The stock later traded at $8.9, down 20.5% from the listing price, with 1.57 million shares changing hands, according to PhillipMart data.
Jiangxi Biological (06915.HK) opened 38.5% higher at $15.51 on the gray market ahead of its June 30 Hong Kong Main Board listing, PhillipMart data shows.
The stock later traded at $8.9, down 20.5% from the listing price, with 1.57 million shares changing hands and turnover of $17.1 million, according to the same data provider. Futu data showed a similar pattern, with the stock opening 33.9% higher at $15 before settling at $12.2, up 8.9% from the listing price, on volume of 1.25 million shares and turnover of $19.18 million.
The divergent gray market prints reflect thin pre-debut liquidity typical of smaller HK listings, where a handful of trades can swing prices sharply. Gray market activity, conducted through broker platforms before official exchange trading, offers an early signal of investor demand but carries limited predictive power for first-day performance. The discrepancy between PhillipMart and Futu data highlights the fragmented nature of gray market pricing across different broker platforms.
The gray market trading comes as China Galaxy Securities said Hong Kong stocks' fundamentals have confirmed an inflection point, though market confidence and fund flows have yet to align. The broader market context may influence Jiangxi Biological's debut reception, with the Hang Seng Index's recent performance shaping investor sentiment toward new listings.
The company's Main Board listing on June 30 will test institutional appetite for the stock. Investors will watch the opening print and early trading volume for signs of sustained demand beyond the gray market. The pricing gives the company a valuation that will be measured against sector peers once trading begins, with first-day performance serving as a key indicator of market reception.
This article is for informational purposes only and does not constitute investment advice.
